Rebecca Aft is an Oncology physician affiliated with Washington University in St. Louis. OpenAlex indexes 343 publications with 14,859 citations (h-index 56); ClinicalTrials.gov lists 6 registered studies matched to this name. By OpenAlex citation count, this profile ranks in the top 10% of Surgical Oncology profiles in the findmyKOL directory.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
4500 Forest Park Ave
Div Surg Oncology, 8th Fl
Saint Louis, MO 631082114
Telephone
314-362-2280Provider last certified this registry record 18 Aug 2025.
Clinical trials
- Endocrine Treatment Alone for Elderly Patients With Estrogen Receptor Positive Operable Breast Cancer and Low Recurrence Score
Sponsor: Washington University School of Medicine
- Effect of Trastuzumab on Disease Free Survival in Early Stage HER2-Negative Breast Cancer Patients With ERBB2 Expressing Disseminated Tumor Cells
Sponsor: Washington University School of Medicine
- LDE225 in Treating Patients With Stage II-III Estrogen Receptor- and HER2-Negative Breast Cancer
Sponsor: Washington University School of Medicine
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
4 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- INTUITIVE SURGICAL, INC.Program year202414 payments
- Intuitive Surgical, Inc.Program year202319 payments
- GE HealthCareProgram year20231 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
86.5%Aromatase Inhibitor86.5%Anastrozole93%Letrozole7%Part D<11 patientsAnti-infectives
13.5%First-generation cephalosporins7.8%Cephalexin100%Part D≥11 patientsTetracycline-class Drug5.7%Doxycycline Hyclate100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
4 NIH research awards on record, funded 1988–2025 per NIH RePORTER. The latest:
- Synergized Immune and Tumor Cell Bone Marrow Biomarkers to Predict Recurrence in Triple Negative Breast Cancer
Washington University
FY2025$653,623R01CA262555 - Synergized Immune and Tumor Cell Bone Marrow Biomarkers to Predict Recurrence in Triple Negative Breast Cancer
Washington University
FY2024$620,943R01CA262555 - Synergized Immune and Tumor Cell Bone Marrow Biomarkers to Predict Recurrence in Triple Negative Breast Cancer
Washington University
FY2023$640,551R01CA262555
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Breast Cancer, Version 3.2024, NCCN Clinical Practice Guidelines in Oncology
Journal of the National Comprehensive Cancer Network
2024 - NCCN Guidelines® Insights: Breast Cancer, Version 4.2023
Journal of the National Comprehensive Cancer Network
2023 - The Liquid Biopsy Consortium: Challenges and opportunities for early cancer detection and monitoring
Cell Reports Medicine
2023 - Breast Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology
Journal of the National Comprehensive Cancer Network
2022
Similar KOLs
Other experts from the same institution or the same specialty.
Randall Bateman, MD
Washington University in St. Louis
Janet McGill, MD
Washington University in St. Louis
Robert Carney, MD
Washington University in St. Louis
David Clifford, MD
Washington University in St. Louis
Carl June, MD
University of Pennsylvania
Rainer Storb
University of Washington
Christina Fitzmaurice, MD
Larry Norton, MD
Memorial Sloan Kettering Cancer Center
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”